title: [Effects of Erigeron breviscapus injection on TNF-alpha, PAI-1 and tPA in rats with acute myocardial infarction].
abstract: OBJECTIVE
  To research the effects of Erigeron breviscapus injection (EBI) on TNF-alpha, PAI-1 and tPA in rats with acute myocardial infarction.
  
  
  METHODS
  Models of acute myocardial infarction (AMI)were produced by ligation of left anterior descending coronary artery, then rats were randomly divided into control and experimental groups, then respectively gavaged NS, and the low, middle and high dosage of EBI for one week. The cardiac function index and the expression of TNF-alpha, tPA and PAI-1 were measured.
  
  
  RESULTS
  Compared with the NS group, the cardiac function LVEDP, MAP, LVPmax, +/- dp/dt of AMI rat was improved by EBI in all dosage range, and the expression of TNF-alpha and PAI-1, LVEDP were decreased (P < 0.05), the expression of tPA, MAP, LVPmax and +/- dp/dt were increased obviously (P < 0.05) and had a dose-effect relationship.
  
  
  CONCLUSIONS
  EBI can inhibit the expression of TNF-alpha and PAI-1, increase the expression of tPA,which can prevent the ongoing thrombopoiesis after AMI and improve the cardiac function. This maybe attributes to the inhibition of the overexpression of TNF-alpha.
authors.affiliation: The First People's Hospital of Shunde, Foshan 528300, China. hkwen@21cn.com
authors.forename: Kai-Wen
authors.initials: KW
authors.lastname: Huang
authors.forename: Jie-Wen
authors.initials: JW
authors.lastname: Guo
authors.forename: Jian-Mei
authors.initials: JM
authors.lastname: Chen
authors.forename: Guang-Qing
authors.initials: GQ
authors.lastname: Qiu
authors.forename: Zhi-Jun
authors.initials: ZJ
authors.lastname: Deng
authors.forename: Li-Ming
authors.initials: LM
authors.lastname: Li
authors.forename: Yong-Heng
authors.initials: YH
authors.lastname: Fu
mesh_terms: D000208:Acute Disease; D000818:Animals; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D049919:Erigeron / Q000737:chemistry; D007267:Injections; D008297:Male; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D009206:Myocardium / Q000378:metabolism* / Q000473:pathology; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood / Q000378:metabolism*; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D010959:Tissue Plasminogen Activator / Q000097:blood / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000097:blood / Q000378:metabolism*
chemical_list: D004365:Drugs, Chinese Herbal; D017395:Plasminogen Activator Inhibitor 1; D014409:Tumor Necrosis Factor-alpha; D010959:Tissue Plasminogen Activator